Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Biovail and Acadia Pharmaceuticals are joining to commercialize pimavanserin, a drug developed by Acadia to treat psychosis caused by Parkinson's disease. It is currently in Phase III clinical trials. Biovail will make a $30 million up-front payment plus milestone payments for commercial achievements. Acadia could get up to $395 million. Separately, Biovail will acquire U.S. rights to GlaxoSmithKline's antidepressant Wellbutrin XL for $510 million. The drug, now off patent, was developed by Biovail.
This article has been sent to the following recipient: